Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Long-term Care Clear all
Active, not recruiting No phase listed Observational

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

NCT05714514
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 4 Interventional Results available

ADA Linagliptin in Long Term Care

NCT02061969
View directory record Official record
Conditions
Diabetes
Interventions
linagliptin, insulin glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 23, 2026, 12:40 PM EDT
Withdrawn No phase listed Observational

Implementation of AIP Services for Older Adults With AD

NCT07361601
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

NCT03537651
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting No phase listed Observational

Pilot Study to Evaluate the Long-term Chronic Care of Patients Who Could or do Utilize an Osseointegrated Device (OID)

NCT04899037
View directory record Official record
Conditions
Hearing Loss, Conductive, Hearing Loss, Mixed, Deafness, Unilateral
Interventions
No intervention
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of GSK1605786A

NCT01318993
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

NCT06260709
View directory record Official record
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions
NNC6019-0001
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

NCT00567723
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
2,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
199
States / cities
Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 23, 2026, 12:40 PM EDT
Recruiting No phase listed Observational

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

NCT06192576
View directory record Official record
Conditions
Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Interventions
Olipudase alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 2 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

The SUCCEED Trial of Secondary Stroke Prevention

NCT01763203
View directory record Official record
Conditions
Stroke, Secondary Stroke Prevention
Interventions
Care Management+Community Health Worker, Usual Care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Downey, California • Los Angeles, California • Sylmar, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 23, 2026, 12:40 PM EDT
Not listed Not applicable Interventional

Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

NCT00377078
View directory record Official record
Conditions
Clostridium Difficile
Interventions
recombinant human lactoferrin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2006 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

NCT00947297
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
HPN-100
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study

NCT02735382
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Smoking
Interventions
Tobacco quitline EHR referral, Tobacco quitline Fax referral
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
14,930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Directly Observed and Long-term Varenicline

NCT03365362
View directory record Official record
Conditions
Tobacco Use Disorder, Opioid-use Disorder
Interventions
Long-Term Varenicline, Short-Term Varenicline, Directly Observed Therapy, Self Administered Therapy
Drug · Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 2Phase 3 Interventional

Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities

NCT00280943
View directory record Official record
Conditions
Hip Fractures, Osteoporosis
Interventions
Long-term care facilities in the intervention arm will receive education and feedback audit on performance
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional

Promoting Seniors' Health With Home Care Aides

NCT03301116
View directory record Official record
Conditions
Muscle Weakness
Interventions
Healthy Moves for Aging Well (Healthy Moves), Active Mind for Aging Well (Active Mind)
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years to 110 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

iADAPT: Off Label Use of Antipsychotics in the Nursing Home

NCT01347619
View directory record Official record
Conditions
Off-label Use of Atypical Antipsychotic Drugs
Interventions
Toolkit only with Web Access to Online Version, Toolkit, Periodic Audit/Feedback, Educational Messages, Items in Arm 2 plus Academic Detailing Program
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rocky Hill, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Sep 23, 2026, 12:40 PM EDT
Completed No phase listed Observational

Long Term Outcomes in β Thalassemia Major

NCT02307786
View directory record Official record
Conditions
Thalassemia Major
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
0 Years to 30 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Withdrawn Phase 4 Interventional

Comparative Effectiveness Study of MIST Therapy Versus Negative Pressure Wound Therapy

NCT01200563
View directory record Official record
Conditions
Wounds
Interventions
MIST Therapy, Vacuum Assisted Closure, MIST Therapy and Negative Pressure Wound Therapy
Device
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2014 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting Phase 2 Interventional

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230
View directory record Official record
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 23, 2026, 12:40 PM EDT
Active, not recruiting No phase listed Observational

Long Term Follow up of Children Enrolled in the REDvent Study

NCT03709199
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Ventilator-Induced Lung Injury, Neurocognitive Dysfunction, Quality of Life, Respiration Disorders
Interventions
Ventilation Inhomogeneity, Diaphragm Ultrasound, Respiratory Inductance Plethysmography, Spirometry, Functional Residual Capacity, MIP/MEP, 6 minute walk test, Neurocognitive Testing, Emotional Health Assessment, Health Related Quality of Life, Functional Status, Respiratory Status Questionnaire
Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Month to 18 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 23, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

Changing the Healthcare Delivery Model

NCT02093234
View directory record Official record
Conditions
Diabetes Type 2
Interventions
mobile health care application, CHWs and mobile health care application, Community Health Worker (CHW)
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 23, 2026, 12:40 PM EDT